Marshall Wace LLP Invests $615,000 in ImmunityBio, Inc. (NASDAQ:IBRX)

Marshall Wace LLP purchased a new position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 240,311 shares of the company's stock, valued at approximately $615,000.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of ImmunityBio by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 17,328,229 shares of the company's stock worth $44,360,000 after buying an additional 425,713 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in ImmunityBio by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,276,673 shares of the company's stock valued at $3,268,000 after purchasing an additional 10,692 shares during the period. Clearwater Capital Advisors LLC lifted its stake in shares of ImmunityBio by 75.4% in the 4th quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company's stock valued at $2,167,000 after purchasing an additional 363,870 shares during the last quarter. Barclays PLC boosted its holdings in shares of ImmunityBio by 9.8% in the 4th quarter. Barclays PLC now owns 396,484 shares of the company's stock worth $1,015,000 after purchasing an additional 35,448 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of ImmunityBio by 9.2% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 295,950 shares of the company's stock valued at $793,000 after purchasing an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IBRX. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target for the company. HC Wainwright restated a "buy" rating on shares of ImmunityBio in a report on Monday. Finally, D. Boral Capital reiterated a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $12.19.

ImmunityBio Stock Performance

IBRX stock traded up $0.05 during midday trading on Thursday, reaching $1.94. The company's stock had a trading volume of 2,280,485 shares, compared to its average volume of 5,295,634. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $9.16. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -2.11 and a beta of 0.33. The stock has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $3.40.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. As a group, analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.